$BNTX · BioNTech SE
BioNTech reported Q3 2026 results: revenue of €1.29 billion (down 15.1% YoY from €1.52B), net profit of €184.5 million (€0.73 diluted EPS) versus a €28.7M loss in Q3 2025. For the nine months ended September 30, 2026, revenue was €1.51 billion (down 22.9% YoY) with a net loss of €1.17 billion. The quarterly profit was driven by sharply lower other operating expenses (€163.6M vs €729.5M YoY) and strong finance income of €105.3M.
- Q3 revenue €1.29B vs €1.52B YoY (-15.1%), nine-month revenue €1.51B vs €1.96B YoY (-22.9%)
- Q3 net profit €184.5M (€0.73 diluted EPS) vs net loss €28.7M YoY; nine-month net loss €1.17B
- R&D expenses surged to €748.1M in Q3 (+32.5% YoY) and €1.86B for nine months (+16.0% YoY)
- Cash and equivalents stood at €10.2B as of September 30, 2026, up from €7.68B at year-end 2025
- Other operating expenses fell sharply to €163.6M in Q3 from €729.5M YoY, reflecting reduced settlement/impairment charges
Extended-hours trading shows BNTX at $89.89, +2.70% vs the $87.53 regular close, suggesting the market is rewarding the return to quarterly profitability and the sharp drop in other operating expenses despite the YoY revenue decline.
BioNTech's swing to quarterly profit after heavy losses signals operational leverage improving, but the €1.17B nine-month loss and pending EP'949 patent ruling keep risk elevated.
BioNTech's Q3 profit contrasts with the broader post-COVID vaccine revenue normalization hitting mRNA peers; the €748M quarterly R&D spend signals aggressive pipeline investment in oncology and infectious disease as COVID vaccine revenues continue to decline.
Moderna litigation: Düsseldorf Regional Court found infringement of EP'949 against BioNTech and Pfizer in March 2025; EPO Technical Board of Appeal issued preliminary opinion in May 2026 that EP'949 is likely invalid, with oral hearing held September 8-9, 2026 — outcome pending. Prior settlements with NIH ($791.5M) and UPenn (up to $467M) highlight ongoing royalty dispute exposure.